Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Extreme sleep duration may up mortality risk in individuals with T2D

Audrey Abella
20 Oct 2020

Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.

“There is some preliminary evidence that the associations between sleep duration and mortality risk are different between people with and without diabetes,” said the researchers.

Compared with nondiabetic individuals who slept for 7 hours daily (reference duration), those with T2D who slept for 5 and 10 hours/day had higher risks of all-cause mortality (hazard ratios [HRs], 1.63 and 2.17 for ≤5 and ≥10 hours/day, respectively; p<0.001 for both). [Diabetologia 2020;doi:10.1007/s00125-020-05214-4]

In participants with T2D, those who slept for 5 and 10 hours/day had increased mortality risk vs those who slept for 7 hours daily (HRs, 1.24 and 1.83, respectively; p<0.001 for both).

“Our findings suggest that excessive or insufficient amounts of sleep may be risk factors for all-cause … mortality in people with T2D … This population may benefit from targeted sleep-related interventions to reduce the risks of adverse health outcomes,” they added.

 

Too much, too little sleep: both bad?

“[E]xtreme sleep duration may reflect poorer health status and reduced functioning,” said the researchers. On one hand, longer sleep duration is tied to chronic inflammatory responses, which accelerate diabetes progression and its complications, consequently increasing mortality risk, they added.

On the other, inadequate sleep in healthy adults is tied to slower glucose clearance rate and higher sympathetic nervous system activity, with the latter influencing insulin resistance and obesity. [Lancet 1999;354:1435-1439; Am J Hypertens 2001;14:103S–115S; Diabetes Obes Metab 2004;6:85-94; Hypertens Res 2012;35:4-16] “Therefore, sleep deprivation in people with T2D is likely to exacerbate complications and affect the control and management of blood glucose, which drive excess mortality risk,” they explained.

 

Do interventions work?

Six to 8 hours is the recommended sleep duration, be it among the general population or among individuals with T2D. [Sleep Med Rev 2017;32:28-36; Sleep Med 2011;12:215-221] “Monitoring of sleep duration may serve as a useful tool for identifying high-risk people with T2D in clinical practice for possible intervention,” said the researchers.

“However, evidence for the effectiveness of sleep interventions for improving clinical outcomes in people with T2D is complex,” the researchers noted. For instance, CPAP* – an intervention for obstructive sleep apnoea (OSA) – has been shown to improve insulin resistance and glycaemic control in individuals with T2D and OSA for 6 months; however, this benefit was not seen with shorter (3 months) CPAP use. [Am J Respir Crit Care Med 2016;194:476-485; Thorax 2007;62:969-974] “[As such,] sleep interventions as an adjunct to standard diabetes treatment may warrant further attention,” they stressed.

The study population comprised 273,029 adults who participated in the US NHIS** (n=24,212 with T2D). Participants were asked regarding the average number of sleep hours they get daily. However, the use of self-reporting without objective measurements may have influenced the findings, noted the researchers. Also, given the observational nature of the study, “the current study cannot infer causality of the sleep-mortality association among people with T2D.”

There is also insufficient data on sleep quality and other factors*** potentially responsible for poor sleep quality. “This precludes in-depth analysis in relation to sleep problems and mortality in people with T2D. Further studies in this area should concentrate on addressing such issues,” they added.

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).